All Themes

Healthcare affordability activity is coalescing around stricter proof of value: CMS is tightening prior authorization transparency for MA, Medicaid managed care, and marketplace plans, while stakeholders are pressing CMS to balance payment restraint with access protections in CY 2027 rate-setting and outpatient reimbursement. For VBC leaders, the signal is that “cost control” is moving beyond broad population-management claims toward measurable savings and quality evidence—reinforced by Mathematica’s joint replacement work on reducing Medicare episode spending without harming quality and PHTI’s finding that virtual CKD management has not materially slowed progression or reduced costs. The strategic tension is clear: payers and CMS are demanding stronger affordability ROI from digital health and specialty-care models, while provider groups seek guardrails so utilization management and reimbursement updates do not undermine access to complex care such as oncology ([CMS prior authorization transparency](https://www.hfma.org/revenue-cycle/cms-prior-authorization-transparency-requirements/); [Mathematica joint replacement evaluation](https://www.mathematica.org/casestudy/reducing-medicare-joint-replacement-spending-while-maintaining-quality)).

CMS is moving Medicare payment policy toward stronger primary care and technology-enabled chronic care management, with the CY 2027 PFS/MSSP rule drawing stakeholder pressure to strengthen ACO participation, reduce burden, and rebalance payment away from procedural care toward longitudinal population health. At the same time, the Trump administration is expanding CMMI’s ACCESS model in 2027 to additional chronic conditions such as COPD, substance use disorder, and tobacco cessation, signaling a push for scalable, condition-based payment experiments and potential cross-payer alignment for high-cost populations ([ACCESS expansion](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/)). For VBC stakeholders, the upside of new primary care and chronic-condition payment opportunities is being paired with tighter Medicare Advantage risk-adjustment enforcement, including OIG audits and large settlements, raising the strategic importance of coding governance, documentation integrity, and compliance infrastructure.

CMS is pushing value-based contracting toward technology-enabled specialty and chronic-condition management: the ACCESS model is slated to expand in 2027 to COPD, substance use disorder, and tobacco cessation, while agency officials are also signaling interest in broader cross-payer alignment—raising the stakes for providers’ data, care management, and outcomes infrastructure ([Healthcare Dive](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/)). At the same time, major provider and VBC coalitions are using the CY 2027 Physician Fee Schedule/MSSP comment cycle to press CMS for stronger accountable care incentives, lower administrative burden, better interoperability, and primary care investment, reflecting a sector-wide push to make MSSP and adjacent models more scalable rather than simply adding new demonstrations ([Premier](https://premierinc.com/newsroom/policy/premier-provides-cms-feedback-on-physician-payment-and-value-based-care-proposals-for-cy-2027)). The large Medicare Advantage risk-adjustment settlement involving The Villages Health System adds a sharper compliance backdrop: VBC organizations and MA-aligned providers face growing pressure to prove that coding, documentation, and population health activities translate into legitimate clinical accountability, not just revenue optimization.

CMS under the Trump administration is continuing to hardwire specialty and ambulatory care into mandatory/structured value-based payment, with the 2027 Ambulatory Specialty Model participant list signaling a broader push beyond primary-care ACOs into episode- and specialty-focused accountability, while oncology and cardiology stakeholders press for guardrails to prevent reimbursement changes from destabilizing complex care access. At the same time, Medicare Advantage is entering a sharper profitability-and-compliance reset: CMS finalized a 2.48% MA payment increase for 2027, but plans are still pruning products and tightening markets as enforcement pressure rises after the DOJ’s $542M settlement over alleged MA overbilling at The Villages Health, underscoring risk-adjustment exposure for payer-provider VBC platforms ([settlement](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/)). For ACOs and enablement companies, the strategic center of gravity is shifting toward defensible savings, coding integrity, and practical AI adoption—Aledade’s positioning around AI and the ACCESS model reflects growing demand for infrastructure that can manage downside risk without triggering the utilization, documentation, or technology-efficacy concerns now visible in virtual CKD and MA markets ([Aledade](https://news.google.com/rss/articles/CBMilAFBVV95cUxOYmhSTDhPd05CUG1jSWd2MEJUOTBIdmh

CMS is widening the care-coordination aperture in VBC: the new LEAD model extends REACH-like accountable care mechanics into a structure that creates a clearer role for home health agencies, while TEAM and the coming CJR-X era are pushing hospitals to manage post-acute networks more deliberately as cost, quality, and episode outcomes become harder-wired into payment. At the same time, Medicaid ACO experience in maternal health shows that care coordinators can improve quality only when ACOs have actionable data, aligned incentives, and community partnerships—underscoring a strategic tension for health systems and payers between model participation and the operational infrastructure needed to manage high-risk populations across settings. See: [LEAD and home health](https://www.mcknightshomecare.com/news/new-lead-model-builds-on-reach-offers-role-for-home-health-agencies/) and [Medicaid ACOs and maternal health quality](https://www.milbank.org/quarterly/articles/how-medicaid-accountable-care-organizations-advance-maternal-health-care-quality-drivers-of-change-and-challenges-from-the-perspective-of-aco-leaders-clinicians-and-care-coordinators/).

CMS is tightening the link between quality measurement, chronic disease management, and payment: the Trump administration is expanding the technology-enabled ACCESS model in 2027 to include COPD, substance use disorder, and tobacco cessation, while signaling interest in broader cross-payer alignment and scalable population health infrastructure for chronic care ([ACCESS expansion](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/)). At the same time, draft 2027 Medicare Advantage Star Ratings thresholds are becoming harder to meet, and stakeholders including Premier and the Health Care Transformation Task Force are pressing CMS on the CY 2027 PFS/MSSP rule to reduce administrative burden, strengthen primary care and accountable care participation, and maintain quality accountability without overwhelming providers ([MA Stars thresholds](https://www.healthcaredive.com/news/medicare-advantage-stars-cutpoints-2027-cms/829963/)). For ACOs, MA plans, and health systems, the strategic direction is clear: quality performance is becoming more demanding and more operationally embedded, with success increasingly dependent on interoperable data, chronic-condition management capabilities, and measurable outcomes across Medicare and Medicaid populations.

CMS is pushing interoperability from compliance aspiration into operational infrastructure for VBC: prior authorization transparency and FHIR-enabled electronic prior authorization requirements are tightening across Medicare Advantage, Medicaid managed care, and ACA marketplace plans, while NCQA’s move of Transitions of Care into ECDS reporting signals accelerating migration of quality measurement from hybrid/manual abstraction to digital clinical data exchange. At the same time, CMS’s WISeR AI prior authorization pilot is exposing the execution risk of using AI to automate utilization management—reported delays and technical failures sharpen the tension between administrative simplification and potential care disruption, especially for ACOs and risk-bearing groups dependent on timely specialty access and accurate attribution of avoidable utilization ([WISeR concerns](https://www.fiercehealthcare.com/regulatory/delays-tech-failures-abound-cms-wiser-ai-prior-auth-pilot-documents-show); [CMS prior auth transparency](https://www.hfma.org/revenue-cycle/cms-prior-authorization-transparency-requirements/)). For health systems and ACOs, the strategic positioning is clear: invest in FHIR connectivity, ECDS-ready quality infrastructure, and prior auth workflow governance now, because payer-facing interoperability is becoming inseparable from performance in MA, Medicaid, MSSP/ACO models, and emerging digital quality measurement regimes.

CMS is broadening the ACCESS Model to additional chronic conditions, signaling that the Trump administration’s CMS under Dr. Mehmet Oz and CMMI Director Abe Sutton is positioning specialty population-health models around cross-payer alignment, chronic disease management, and Medicaid participation rather than isolated Medicare pilots ([CMS ACCESS expansion](https://www.fiercehealthcare.com/regulatory/cms-extends-access-model-more-chronic-conditions-cms-officials-eye-expansion-medicaid)). In parallel, payers and providers are tightening condition-specific VBC plays—DaVita’s expanded Humana CKD partnership, SCAN’s Walmart Medicare Advantage strategy, and rural systems preparing for value-based care—while measurement infrastructure is also shifting as NCQA uses Komodo data and AI to develop future HEDIS measures. The strategic tension for ACOs and risk-bearing organizations is that chronic-condition VBC is gaining policy and commercial momentum, but evidence remains uneven, particularly in virtual CKD solutions, forcing leaders to distinguish scalable population-health infrastructure from vendor-led disease management that may not improve outcomes or total cost of care.

Medicaid VBC is being pulled in two directions: states and Medicaid ACOs are using accountable care infrastructure to improve maternal health, integrate care coordination, and target disparities, while new Section 1115 budget-neutrality guidance and coverage-risk analyses tied to work requirements signal tighter federal constraints on Medicaid financing and enrollment stability. For ACOs, MCOs, and safety-net systems, the strategic issue is whether population-health investments—especially maternal health, SDoH supports, and digital quality measurement—can be sustained if churn rises among expansion adults and young adults with unstable work or documentation patterns. At the same time, models such as Indiana’s Medicaid GLP-1 coverage through the federal BALANCE Model point to a continued push to test value-based approaches for high-cost chronic disease interventions, but under sharper scrutiny around ROI, equity impact, and state budget exposure ([Milbank on Medicaid ACOs and maternal health](https://www.milbank.org/quarterly/articles/how-medicaid-accountable-care-organizations-advance-maternal-health-care-quality-drivers-of-change-and-challenges-from-the-perspective-of-aco-leaders-clinicians-and-care-coordinators/); [SHVS on Section 1115 budget neutrality](https://shvs.org/resources/new-budget-neutrality-guidance-for-medicaid-section-1115-demonstrations/)).

CMS is repositioning primary care as the next major lever for Medicare value-based care: the CY 2027 Physician Fee Schedule and MSSP proposals begin a two-year effort to address longstanding primary care undervaluation while tying those changes to accountable care growth, beneficiary access, and more sustainable ACO participation ([HFMA](https://www.hfma.org/payment-reimbursement-and-managed-care/2027-medicare-primary-care-payment/); [HCTTF](https://hcttf.org/the-task-force-provides-input-to-cms-on-the-cy-2027-physician-fee-schedule-medicare-shared-savings-program-proposed-rule/)). At the same time, CMS is expanding model-based infrastructure around ACCESS, LEAD, REACH, and TEAM, signaling that under the Trump administration’s CMS leadership, federal models—not Medicare Advantage plans—are becoming the more active engine for primary care, chronic-condition management, and post-acute integration as MA plans retrench. For ACOs, health systems, and payer partners, the strategic tension is whether new primary care payments and model expansions will be sufficient to offset operational burden, specialty/post-acute fragmentation, and the need for cross-payer alignment.

CMS is moving on two fronts: expanding CMMI’s ACCESS model in 2027 to additional chronic conditions—including COPD, substance use disorder, and tobacco cessation—while stakeholders press CMS to use the CY 2027 Physician Fee Schedule and MSSP rulemaking to strengthen primary care, reduce ACO administrative burden, and improve interoperability. At the same time, MA risk-adjustment enforcement is intensifying through OIG audits and the DOJ’s $542 million Villages Health settlement, raising the stakes for documentation, coding governance, and provider-payer VBC contracts tied to diagnosis capture. Together, the signal for VBC leaders is clear: the Trump administration’s CMS is broadening technology-enabled chronic care payment models while tightening accountability around risk coding and savings attribution. [CMS expanding ACCESS model](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/) | [Villages Health MA settlement](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/)

Payment integrity pressure is intensifying across Medicare Advantage and Medicare FFS, with OIG diagnosis-code audits of UnitedHealthcare and Humana contracts reinforcing CMS and DOJ scrutiny of risk adjustment, while the $541.5M Villages Health settlement signals that provider groups participating in MA-aligned value-based arrangements face direct False Claims Act exposure for unsupported coding and chart-review practices ([Healthcare Dive](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/)). In parallel, CMMI under Abe Sutton is positioning the WISeR prior authorization model as a broader template for reducing wasteful services, creating a strategic tension for ACOs and risk-bearing providers: payment integrity tools may protect benchmarks and trust-fund dollars, but AI-enabled utilization controls and implementation failures could increase administrative burden and disrupt care-management workflows ([HFMA](https://www.hfma.org/cmmi-head-wiser-should-serve-as-model/)).

CMS is moving utilization management deeper into federal payment policy: CMMI Director Abe Sutton is positioning the controversial WISeR Medicare prior authorization pilot as a template for broader federal program use, even as reporting on implementation delays and technology failures intensifies concerns about AI-enabled PA becoming a new administrative choke point for providers and ACO-aligned specialists ([HFMA](https://www.hfma.org/cmmi-head-wiser-should-serve-as-model/); [Fierce Healthcare](https://www.fiercehealthcare.com/regulatory/delays-tech-failures-abound-cms-wiser-ai-prior-auth-pilot-documents-show)). In parallel, CMS is tightening prior authorization transparency requirements for Medicare Advantage, Medicaid managed care, and marketplace plans, signaling a dual-track strategy: expand UM as a program-integrity and cost-control lever while forcing plans and vendors to expose denial, timing, and electronic PA performance data. For VBC stakeholders, the strategic risk is that utilization management will increasingly shape attribution economics, specialist access, and total-cost-of-care performance—especially in MA and high-cost service lines such as oncology, DME, and hospital outpatient care—making PA governance, documentation infrastructure, and appeals workflows core operating capabilities rather than back-office functions.

Medicare Advantage Stars and risk adjustment are moving into a more punitive operating environment: CMS’ draft 2027 Star Ratings cut points would make roughly half of thresholds harder to reach, pressuring MA plans’ quality bonus revenue just as DOJ/OIG scrutiny of diagnosis coding intensifies. The recent [$541.5 million Villages Health settlement](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/) and OIG audits of UnitedHealthcare and Humana contracts reinforce that risk-bearing providers, MSOs, and MA-aligned VBC groups face rising downside exposure when documentation, coding, and chart-review programs are not tightly governed. For ACOs and population-health organizations, the strategic signal is clear: as MA plans pull back and CMS tightens both Stars performance and coding integrity, durable VBC economics will depend less on retrospective revenue optimization and more on auditable care management, compliant risk adjustment, and measurable outcomes under CMS-led models and stricter MA oversight, including the [harder 2027 Stars thresholds](https://www.healthcaredive.com/news/medicare-advantage-stars-cutpoints-2027-cms/829963/).

Risk adjustment is moving from an actuarial/payment-accuracy issue to a core enforcement and VBC contracting risk: OIG audits of Medicare Advantage diagnosis submissions and the $541.5M Villages Health settlement signal that DOJ/CMS scrutiny is increasingly focused on provider-enabled MA coding infrastructure, chart review practices, and unsupported HCC capture—not just payer conduct ([Villages settlement](https://www.healthcaredive.com/news/the-villages-health-medicare-overbilling-settlement-doj-humana/828915/)). At the same time, policy work such as Duke-Margolis’ Medicare risk-adjustment modernization agenda points toward longer-term reform of coding incentives, model calibration, and data validation, creating strategic pressure for ACOs, MA-aligned providers, and delegated-risk groups to tighten documentation governance while preparing for less coding-sensitive payment models ([Duke-Margolis](https://healthpolicy.duke.edu/publications/vision-modernizing-medicare-risk-adjustment-building-evidence-reform)). Stricter 2027 MA Star Ratings thresholds add another margin squeeze for plans and risk-bearing providers, intensifying the tension between legitimate population health documentation, quality performance, and enforcement exposure.

CMS’s CY 2027 Physician Fee Schedule/MSSP rulemaking is positioning primary care investment and accountable care participation as linked priorities, with stakeholders pressing the Trump administration’s CMS to pair higher primary care valuation with lower MSSP administrative burden, better interoperability, and payment policies that sustain innovation without weakening quality accountability ([Premier comments](https://premierinc.com/newsroom/policy/premier-provides-cms-feedback-on-physician-payment-and-value-based-care-proposals-for-cy-2027); [HCTTF comments](https://hcttf.org/the-task-force-provides-input-to-cms-on-the-cy-2027-physician-fee-schedule-medicare-shared-savings-program-proposed-rule/)). At the same time, CMMI’s new ACO LEAD model is being framed as a successor that builds on ACO REACH—expanding the strategic aperture toward Medicare-Medicaid alignment, Medicaid risk contracting, and broader roles for home health and post-acute providers—signaling that ACO strategy is moving beyond Medicare shared savings toward multi-payer, whole-person risk infrastructure.

CMS under the Trump administration is pushing CMMI toward more technology-enabled, condition-specific payment models: the ACCESS model is slated to expand in 2027 to COPD, substance use disorder, and tobacco cessation, while officials are signaling interest in cross-payer alignment across Medicare and Medicaid—an important cue for ACOs and risk-bearing groups building chronic care, digital monitoring, and behavioral health capabilities ([Healthcare Dive](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/)). At the same time, CMMI is testing a more aggressive utilization-management posture through WISeR, with CMMI Director Abe Sutton positioning AI-enabled prior authorization as a broader template despite provider concerns over delays and technology failures, creating a strategic tension between payment innovation, administrative burden, and trust in automated medical-necessity review ([HFMA](https://www.hfma.org/cmmi-head-wiser-should-serve-as-model/)). Parallel moves around LEAD/REACH, ambulatory specialty models, and CJR-X point to a longer-term shift from broad ACO-only transformation toward a portfolio of episode, specialty, home-based, and tech-enabled models that will reward organizations able to integrate care management, post-acute coordination, data infrastructure, and downside-risk operations.

Managed care complexity is becoming a core operating constraint for health systems and ACO-aligned providers, pushing revenue cycle, utilization management, and prior authorization from back-office functions into enterprise VBC infrastructure—especially as leaders seek tighter linkage between documentation, contract performance, denial prevention, and risk-bearing economics ([Premier](https://premierinc.com/newsroom/insights/how-managed-care-is-changing-what-it-means-to-lead-a-health-system); [AMA](https://www.ama-assn.org/practice-management/ama-steps-forward-program/pearl-week-build-stronger-revenue-cycle-value-based)). At the same time, AI-enabled prior authorization, outpatient workflow tools, and SNF workforce automation are being positioned as levers to absorb labor shortages and payer friction, but the strategic tension is whether these tools reduce administrative burden and improve care coordination—or simply intensify payer-provider adjudication in value-based contracts. For VBC stakeholders, the near-term differentiator is operational readiness: integrating RCM, UM, clinical documentation, and workforce redesign around contract requirements rather than treating them as separate compliance or staffing problems.

CMS is moving bundled payments from episodic pilots toward a broader mandatory accountability infrastructure, with TEAM creating near-term pressure on hospitals, orthopedic groups, and post-acute partners to manage surgical episodes while CJR-X signals a longer runway toward expanded joint-replacement accountability by 2028. The strategic tension for providers is that bundled-payment readiness now requires tighter post-acute steering, home health integration, data infrastructure, and compliance capacity, even as hospitals face rising administrative burden from mandatory VBP programs; home health agencies are positioning TEAM as an opening to prove downstream value in episode cost and quality performance ([TEAM and home health opportunity](https://www.mcknightshomecare.com/news/team-demo-gives-home-health-opportunity-to-prove-post-acute-care-value/), [CJR-X readiness](https://premierinc.com/newsroom/insights/cjr-x-is-the-future-of-value-based-care)). Commercial actors are also extending bundled-payment logic beyond Medicare orthopedics into high-cost specialty care, including oncology therapies, reinforcing that episode-based contracting is becoming a cross-market strategy rather than a CMS-only payment experiment.

Payer strategy is bifurcating as Medicare Advantage margins, ACA exchange exposure, and regulatory scrutiny push plans toward more selective growth, tighter network and utilization management, and sharper segmentation by line of business—creating new contracting pressure for VBC providers that depend on MA and marketplace attribution ([Moody’s payer outlook via Fierce](https://www.fiercehealthcare.com/payers/moodys-look-payers-diverging-paths-ma-aca-markets)). At the same time, CMS under the Trump administration is expanding payer-facing transparency and quality accountability, including updated prior authorization transparency guidance and all-payer SNF quality reporting, signaling that administrative friction, post-acute performance, and cross-payer data visibility will become more central to value-based contracting and population health management ([CMS prior auth guidance coverage](https://www.healthleadersmedia.com/revenue-cycle/cms-issues-updated-guidance-prior-auth-transparency-rules-payers)). The broader market is also moving toward more vertical integration and retail-channel distribution—e.g., Costco’s SCAN Medicare Advantage partnership—raising the stakes for ACOs and health systems to prove measurable access, affordability, and outcomes value as payers consolidate more financing, care navigation, pharmacy, and consumer acquisition capabilities.

Specialty VBC momentum is shifting toward kidney disease and heart failure as payers and specialty societies operationalize condition-specific risk arrangements: Humana is expanding a kidney-care partnership targeting 10,000 Medicare Advantage members, while cardiology groups are preparing for CMS’ Ambulatory Specialty Model for heart failure through readiness planning focused on attribution, quality measurement, and care-management infrastructure ([ACC readiness guide](https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools-and-Practice-Support/Advocacy-at-the-ACC/E26030-ASM-Readiness-Guide.pdf)). At the same time, the evidence and measurement bar is tightening—PHTI’s finding that virtual CKD management has limited demonstrated impact on progression or costs is creating pushback from digital kidney vendors, while the National Kidney Foundation’s endorsed CKD detection measure points to earlier diagnosis as a prerequisite for accountable specialty models ([PHTI kidney care analysis](https://www.fiercehealthcare.com/digital-health/virtual-ckd-management-solutions-dont-slow-disease-progression-or-lower-costs-phti)). The strategic tension for ACOs, MA plans, and specialty groups is whether they can convert earlier identification and specialty engagement into durable savings despite MA member churn, ESRD payment uncertainty, and growing scrutiny of whether tech-enabled specialty care actually changes total cost of care.

Pharmacy value models are shifting from medication dispensing economics toward reimbursable access, adherence, and clinical-integration infrastructure: enrollment has opened for the ACCESS to Pharmacy Care Program, while pharmacies are investing in revenue-cycle capabilities to bill for clinical services—an important step if ACOs, MA plans, and Medicaid managed care organizations want pharmacy teams tied to outcomes rather than spread/PBM margin alone ([ACCESS to Pharmacy Care Program](https://www.pharmacytimes.com/view/enrollment-now-open-for-access-to-pharmacy-care-program)). At the same time, Amazon Pharmacy’s $50 GLP-1 delivery for Medicare Bridge Program beneficiaries and Humana’s pharmacy-care study signal payer and retailer positioning around high-cost chronic therapies, adherence, and member retention, creating new competitive pressure on traditional pharmacy networks and PBM-mediated care models. The strategic tension for VBC stakeholders is that adherence, rural pharmacy access, SDOH, and specialty-drug coordination are increasingly measurable levers for total cost and quality, but current adherence metrics remain contested and may need redesign before pharmacy performance can be reliably embedded in shared-savings or risk contracts ([adherence metrics scrutiny](https://news.google.com/rss/articles/CBMi1gFBVV95cUxPQXR2ckZTMDFONmJwazg0WEQwRWlCVjNTVVNxdnpBd2QtY0tJWE4tdlBNZXNVSjU4T0tCRTZPUS